Leah Allison Burke MD

Hospital Medicine/Hospitalist, Infectious Disease

Associate Director with the Hospitalist service at Yale New Haven Hospital, Assistant Clinical Professor at Yale School of Medicine

Northeast Medical Group/Yale New Haven Hospital20 York Street. CB 2041New Haven, CT 06510
Phone+1 203-688-4748

Summary

Dr. Leah Burke is an internist in New Haven, CT and is affiliated with multiple hospitals in the area, including Yale-New Haven Hospital and NewYork-Presbyterian/Weill Cornell. She received her medical degree from Boston University School of Medicine. She completed fellowship training in infectious diseases and is experienced in the development of clinical trials for patients with HIV and hepatitis C. She is an Assistant Clinical Professor at the Yale School of Medicine and an Associate Director of the Hospitalist service at Yale New Haven Hospital.

New York Presbyterian Hospital (Cornell Campus)Fellowship, Infectious Disease, 2011 - 2014
Yale-New Haven Medical CenterResidency, Internal Medicine, 2007 - 2010
Boston University School of MedicineClass of 2007

Vice Chair AIDS Clinical Trials Group (ACTG) Monoclonal Antibody Working Group, 2015

PubMed

3 citations
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357.
Babafemi O Taiwo, Yu Zheng, Katherine Rodriguez, Leah Burke, Jacqueline D Reeves
Clinical Infectious Diseases. 2026-02-09
4 citations
Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment
Grant B Ellsworth, Leah A Burke, Martin T. Wells, Satish Mishra, Matthew Caffrey
Journal of Acquired Immune Deficiency Syndromes. 2021-01-01
90 citations
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117.
Yehuda Z. Cohen, Julio C. C. Lorenzi, Lisa Krassnig, John P. Barton, Leah A. Burke
The Journal of Experimental Medicine. 2018-08-02

Journal Articles

Books/Book Chapters

Infectious Diseases
Chapter: Drugs to Treat Viral Hepatitis
Burke LA, Marks KMEditors: Cohen, Powderly, and Opal.Edition 4th,
Encyclopedia of AIDS
Chapter: Entry Inhibitors
Page 1 - 12Burke LA, Gulick RMEditors: Hope, Stevenson, and Richman.2016
Clinical Decision Support in Medicine: Hospital Medicine
Chapter: Foley Catheters
Cho HJ, Burke LAEditors: Miller C, et al..Edition 2nd,2016

Abstracts/Posters

Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Virus Infection in Patients with Human Immunodeficiency Virus.
Burke LA, Fierer DS, Cassagnol D, Hijdra R, Van Seggelen W, and Marks, KM, Infectious Diseases (ID) Week, San Francisco, CA, 10/5/2013

Lectures

Hepatitis C in the Era of Direct Acting Antiviral Therapy (Grand Rounds)
Department of Medicine Grand Rounds at North Shore-LIJ Forest Hills Hospital - 10/21/2015

Other

Acute HCV Treatment in HIV-infected Patients
Burke LA, Marks K, IAS-USA Case on the Web
http://www.iasusa.org/content/treatment-acute-hepatitis-c-virus-infection-hiv-infected-patients
6/5/2015

3BNC117 mAb in HIV-infected Subjects on Combination ARTNIH/NIAID2015–2018
Passive Immunotherapy with Human Anti-HIV Neutralizing Monoclonal AntibodiesBill and Melinda Gates Foundation2013–2017
HIV Adherence Bottle Intervention Trial (HABIT)Health 2.02014–2015

Vice Chair, AIDS Clinical Trials Group Monoclonal Antibody Working Group 2015 - Present
Vice Chair, AIDS Clinical Trials Group A5357 Protocol Development Team 2015 - Present

InvestigatorInvestigator on multiple clinical trials evaluating the use of broadly-neutralizing monoclonal antibodies to treat and prevent HIV infection.2014 - Present
Principal Investigator (HABIT Study)A phase 1 clinical trial, aimed at investigating whether a novel smart pill bottle will improve adherence to antiretroviral medication in patients with HIV, and whether a new laboratory test (tenofovir dried blood spots) will be a good assessment of antiretroviral medication compliance.2014 - 2018